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Abstract 
BACKGROUND: Liver biopsy for evaluation of liver fibrosis has several adverse effects, for which reason 
noninvasive tests have been developed. 
AIM: To evaluate the usefulness of noninvasive biomarkers, qHBsAg and HBV DNA levels in predicting liver 
fibrosis in patients with hepatitis Be antigen (HBeAg) negative chronic hepatitis B (CHB). 
MATERIAL AND METHODS: This prospective study included 50 patients with HBeAg negative CHB. All patients 
underwent laboratory and serology testing, quantification of HBV DNA and HBs antigen. The liver stiffness was 
measured with elastography. The patients were analysed for APRI and FIB-4, quantitative hepatitis Bs antigen 
and HBV DNA. 
RESULTS: Logistic regression analysis showed that greatest significance in predicting liver fibrosis has FIB-4 
(Wald = 3.24, P = 0.07), followed by HBV DNA ≥ 2 000 IU/ml ≤ 20 000 IU/ml (Wald = 2.86, P = 0.09), qHBsAg 
(Wald = 2.17, P = 0.14), HBV DNA > 20 000 IU/ml (Wald = 0.58, P = 0.45), APRI (Wald = 0.04, P = 0.84). 
CONCLUSION: the FIB-4 index has the greatest value in predicting liver fibrosis while APRI has the lowest; the 
more advanced liver disease is associated with lower serum level of quantitative HBs antigen. Combination of 
noninvasive blood biomarkers and imaging tests can provide better diagnostic accuracy and exclude the need for 
liver biopsy. 
 
 
 
 
 
 
 
 
Introduction 
 
Chronic infection with hepatitis B virus (HBV) 
is a global health problem, with over 350 million 
people worldwide affected by it, remaining the 
predominant cause of chronic liver disease and liver-
related morbidity worldwide. This clinical condition is 
considered to be the major risk factor for cirrhosis, 
end-stage liver disease and hepatocellular carcinoma 
(HCC) [1] [2] [3]. Hepatitis Be antigen (HBeAg) 
negative chronic hepatitis B (CHB) is characterised by 
fluctuating levels of hepatitis B virus deoxyribonucleic 
acid (HBV DNA) and aminotransferases, with 
temporary remissions during the disease [4]. HBeAg-
negative CHB patients with active hepatic necrotic 
inflammation and persistent viraemia have higher 
rates of complications in contrast to HBeAg-negative 
patients with CHB who are inactive carriers. Both 
forms of CHB have similar laboratory and serologic 
characteristics and are not always easy to distinguish 
[5]. Assessment of liver fibrosis and its timely 
detection is essential for evaluation of liver disease 
severity. This is of particular importance for decision 
making and starting antiviral therapy and 
consequently preventing the development of CHB 
caused complications [4] [5] [6] [7]. 
Liver biopsy is the standard gold method for 
assessing the stage of the liver diseases. It is an 
invasive procedure, associated with pain and 
complications, where accurate results rely not only on 
the tissue sample quality and size but also of the 
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pathologists’ experience [8]. Recently noninvasive 
methods for predicting liver fibrosis as well as imaging 
techniques, including transient elastography (TE), 
ultrasonography (US), computed tomography (CT) 
and magnetic resonance imaging (MRI) have been 
developed [4][9]. Serum markers for assessing liver 
fibrosis and cirrhosis can be used individually, but 
most of the times are combined to achieve better 
diagnostic sensitivity and specificity. Direct markers 
are representative of liver fibro-genesis and include 
glycoproteins, collagens, collagenases and 
collagenase inhibitors. Indirect markers reflect liver 
damage and correlate with liver fibrosis. They include 
platelet (PLT) count, aspartate transaminase (AST) 
and alanine transaminase (ALT), globulin level, serum 
quantitative HBs antigen (qHBsAg), ceruloplasmin, 
TGF-α, red blood cell distribution width, and serum 
Golgi protein 73 (GP73) [6].  
Fibrosis index (FIB-4) is based on the four 
factors: evaluation of age, AST, platelets and ALT. 
Moreover, the FIB-4 index has been used to evaluate 
significant fibrosis and liver cirrhosis in HBV-infected 
patients in numerous studies [10] [11]. Concerning 
aspartate transaminase-to-platelet ratio index (APRI), 
it was first developed in the study of patients with 
chronic HCV infection [12], but it has been concluded 
that has moderate sensitivity and accuracy when it 
comes to HBV related fibrosis [13] [14]. Evaluation of 
the level of quantitative hepatitis B surface antigen 
(qHBsAg) reflects the amount of transcriptional activity 
of cccDNA and the integrated DNA in the hepatocytes 
[15] [16] representing one of the main serologic 
markers in chronic HBV infection; accurately 
monitoring both disease progression and prognosis as 
well as response to antiviral therapy [17] [18]. In this 
context, several studies have observed the correlation 
between quantitative HBsAg and liver fibrosis 
indicating their mutual correlation [19] [20] [21] [22].  
Moreover, serum HBV DNA levels directly 
reflect the degree of HBV replication and are 
considered a strong prognostic indicator for CHB 
infection. Increasing HBV DNA levels correlate with 
the higher rate of progression to cirrhosis, the 
incidence of hepatocellular carcinoma (HCC), and 
subsequent death from HCC or chronic liver disease 
[23]. However, high HBV DNA levels do not always 
predict significant hepatitis [23]. 
Lastly, transient elastography (TE) is 
performed to measure the speed of the shear wave 
which is directly associated with the liver stiffness. TE 
measures the liver stiffness (LS) which by itself is 
associated with the degree of fibrosis [24] [25].  
In this study, we evaluated the usefulness of 
noninvasive biomarkers FIB-4, APRI, quantitative 
hepatitis B antigen and HBV DNA for prediction of 
liver fibrosis in patients with HBe antigen negative 
chronic hepatitis B. 
 
Material and Methods 
 
A prospective, non-randomized study was 
conducted at the University Clinic for infectious 
diseases and febrile conditions which included fifty 
patients with hepatitis Be negative antigen CHB. The 
inclusion criteria were: age over 18 years, patients 
with serologically confirmed chronic hepatitis B, 
patients who were hepatitis B e antigen negative. All 
patients have been examined at least twice, with a 
minimum follow-up period of at least 6 months. All 
patients signed informed consent. The exclusion 
criteria were co-infection with human 
immunodeficiency virus (HIV), hepatitis A (HAV) and 
hepatitis C (HCV) as well as other liver diseases with 
different aetiology. Patients who had received antiviral 
therapy, patients who are currently on antiviral 
therapy, patients with hepatocellular carcinoma (HCC) 
and patients with liver failure were not included in the 
study.  
All patients underwent standard laboratory 
and serology testing. We evaluated APRI and FIB-4 
score as well as the values of aspartate transaminase 
(AST), alanine transaminase (ALT), qHBsAg, HBV 
DNA and liver fibrosis.  
Relevant clinical variables were age, platelet 
count, ALT, AST, HBsAg, hepatitis B e antigen, HBV 
DNA, and fibroscan. The value of ALT, AST, qHBsAg 
and HBV DNA were expressed in IU/ml. 
Quantification of HBV DNA levels in the 
plasma was performed by real-time polymerase chain 
reaction (RT-PCR) on COBAS AmpliPrep COBAS 
TaqMan HBV test and Abbott m 2000 sp/m 2000 rt 
with a lower detection limit of 10 IU/mL.  
The serum level of HBsAg (qHBsAg) was 
quantified with Architect HBsAg assay (Abbott 
Laboratories) according to the manufacturers’ 
protocol. The detection level of HBsAg varies from 
0.05 to 250 IU/ml. Sera with HBsAg level higher than 
250 IU/ml were diluted 1:500.  
Abdominal ultrasound, as well as transient 
elastography, was performed on all patients. The liver 
stiffness was measured with transient elastography 
(TE); fibroscan (EchoSens
R
, Paris, France) and 
expressed in kilopascals (kPa). The mean value was 
obtained from 10 performed measures, with success 
rate more than 60% and interquartile range (IQR) < 
0.25.  
Aspartate transaminase-to-platelet ratio index 
(APRI) was calculated with the following formula: 
((AST/ULN AST) x100)/Platelets (10
9
/L)). APRI score 
greater than 1.0 has a sensitivity of 76% and 
specificity of 72% for predicting cirrhosis. APRI score 
greater than 0.7 has a sensitivity of 77% and 
specificity of 72% for predicting significant hepatic 
fibrosis. APRI > 1.5 is the cut-off value for significant 
fibrosis, whereas a score <0.5 can rule it out [26]. 
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The fibrosis index (FIB-4) is based on the four 
factors and calculated by the following formula: Age 
(yr.) xAST (IU/ml)/PLT (x10
9
/L) x ALT (IU/ml) 1/2. A 
FIB-4 score <1.45 has a negative predictive value of 
90% in patients with advanced fibrosis. FIB-4 score 
>3.25 has a 97% specificity and a positive predictive 
value of 65 % of patients [10] [11].  
All data were processed using a statistical 
computer program Statistica 7.1 for Windows and 
SPSS Statistics 17.0. For a description of the 
numerical variables descriptive statistics ((Mean; Std. 
Deviation; ± 95, 00%CI; Minimum; Maximum) was 
used, where frequencies and percentages were used 
for the description of the categorical variables.  
To identify the predictive values for FIB-4, 
APRI, qHBsAg and HBV DNA for fibrosis, logistic 
regression analysis (Wald, Exp (B), 95, 0% CI for Exp 
(B), and p) were used. For all analyses, the P-value < 
0.05 was considered statistically significant. 
 
 
Results  
 
A total of 50 chronic hepatitis B treatment 
naïve HBeAg-negative patients were included in the 
study. There were 26% female and 74% male 
patients. The patients’ age ranged from 19 to 67 
years. The platelet count ranges between the intervals 
from 104 to 344 x 10
9
/L.  
The mean values of ALT vary in the interval 
44.42 ± 42.63 IU/ml, and AST value varies in the 
interval of 29.88 ± 18.62 IU/ml. Serum qHBsAg values 
vary in the interval of 6143.21 ± 9372.24 IU/ml; the 
level of HBV DNA vary in the interval of 492303.2 ± 
1642234 IU/ml (Table 1). 
Table 1: Statistical analysis of the patients from the cohort 
 Valid N Mean 
Confidence 
-95.00% 
Confidence 
+95.00% 
Minimum Maximum Std.Dev. 
Age 50 38.820 35.754 41.886 19.0000 67.00 10.787 
Tr 50 208.240 194.391 222.089 104.0000 344.00 48.731 
ALT 50 44.420 32.304 56.536 10.0000 210.00 42.631 
AST 50 29.880 24.589 35.171 13.0000 103.00 18.616 
qHBsAg 50 6143.205 3479.644 8806.767 0.0500 55513.63 9372.241 
HVD DNA 50 492303.2 25585.48 959020.9 24 10451113 1642234 
Abbreviations: Tr: thrombocytes, ALT: alanine aminotransferase, AST: aspartate 
aminotransferase, qHBsAg: quantitative hepatitis B antigen, HBV DNA: hepatitis B virus 
deoxyribonucleic acid 
 
Stratification of the patients according to the 
level of HBV DNA and qHBsAg showed that 50% of 
the patients had HBV DNA level lower than 2 000 
IU/ml, 22% had HBV DNA more or equal to 2 000 
IU/ml and lower or equal to 20 000 IU/ml, and in 28% 
HBV DNA level was higher than 20 000 IU/ml, while 
36% patients had qHBsAg level lower or equal to 1 
000 IU/ml and in 64% the value of qHBsAg was higher 
than 1000 IU/ml (Table 2). 
 
Table 2: Frequency table (%) for HBV DNA, qHBsAg, fibroscan, 
APRI, FIB-4 
HBV DNA  Number 
Cumulative 
Number 
% 
Cumulative 
% 
HBV DNA <2000 IU/ml 
HBV DNA ≥2000≤20 000IU/ml 
HBV DNA >20 000 IU/ml 
Missing 
25 
11 
14 
0 
25 
36 
50 
50 
50.00 
22.00 
28.00 
0.00 
50.00 
72.00 
100.00 
100.00 
qHBsAg Number 
Cumulative 
Number 
% 
Cumulative 
% 
qHBsAg ≤1000 IU/ml 
qHBsAg>1000IU/ml 
Missing 
18 
32 
0 
18 
50 
50 
36.00 
64.00 
0.00 
36.00 
100.00 
100.00 
Fibroscan Number 
Cumulative 
Number 
% 
Cumulative 
% 
f0/f1 
f2/. f2/f3 
f3.f3/f4. f4 
 Missing 
42 
5 
3 
0 
42 
47 
50 
50 
84.00 
10.00 
6.00 
0.0 
84.00 
94.00 
100.00 
100.00 
APRI Number 
Cumulative 
Number 
% 
Cumulative 
% 
APRI>0.7 
APRI<0.7 
Missing 
4 
46 
0 
4 
50 
50 
8.00 
92.00 
0.00 
8.00 
100.00 
100.00 
FIB-4 Number 
Cumulative 
Number 
% 
Cumulative 
% 
FIB 4<1.45 
FIB4>1.45<3.25 
FIB 4>3.25 
Missing 
44 
5 
1 
0 
44 
49 
1 
50 
88 
10 
2 
0.00 
88 
90 
100.0 
100.00 
Abbreviations: HBV DNA: hepatitis B virus deoxyribonucleic acid, qHBsAg: quantitative 
hepatitis B antigen, APRI: Aspartate transaminase-to-platelet ratio index, FIB-4: Fibrosis 
index based on the four factors 
 
Liver stiffness measured with transient 
elastography showed that 84% patients had no 
fibrosis (f0/f1), 10% had intermediate fibrosis (f2 and 
f2/f3), while significant fibrosis (f3, f3/f4 and f4) was 
detected in 6% of the patients (Table 2). 
Aspartate transaminase-to-platelet ratio index 
(APRI score) greater than 0.7 was observed in 8% of 
the patients, while in 92% of them was lower than 0.7. 
For detecting significant fibrosis, APRI scores greater 
than 1.5 was not observed in any patient, while APRI 
scores lower than 0.5 was found in 42 (84%) of the 
patients (Table 2).  
Fibrosis index (FIB-4) based on the four 
factors showed that 88% patients included in our 
study had a FIB-4 score < 1.45, and 2% had a FIB-4 
score > 3.25 (Table 2).  
The predictive values of APRI, FIB-4, qHBsAg 
and HBV DNA were evaluated for fibrosis, using the 
model of discrimination. The global accuracy of this 
model in predicting fibrosis is 90.00% with a sensitivity 
of 55.60% and specificity of 97.60% (Table 3). 
Table 3: Model of discrimination -Prediction of fibrosis with 
APRI, FIB-4, HBsQ, HBsQ, HBV DNA 
 
Observed 
Predicted 
 Fibrosis 
Percentage 
Correct  Absence Presence 
Step 1 Fibrosis Presence 40 1 97.6 
Absence 4 5 55.6 
Overall Percentage   90.0 
a. The cut value is 500; The global accuracy of this model for predicting liver fibrosis is 86, 
00%. Sensitivity is 44.40%, and specificity is 95.10% 
 
Table 4 reports the data obtained through 
logistic regression analysis which showed that FIB-4 
has the greatest significance in this model (Wald = 
3.24, P = 0.07), followed by intermediate high level of 
HBV DNA ≥ 2 000 IU/ml ≤ 20 000 IU/ml (1) (Wald = 
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2.86, P = 0.09), qHBsAg (Wald = 2.17, P = 0.14), HBV 
DNA >20 000 IU/ml (1) (Wald = 0.58, P = 0.45), while 
APRI has the lowest prediction for liver fibrosis, (Wald 
= 0.04, P = 0.84).  
Logistic regression analysis showed that the 
increase of FIB-4 for one single cut-off value 
enhances the probability for fibrosis for 9.34 (Exp (B) 
=9.34)/(834%) insignificant in 95% CI for EXP (B): 
0.82-106.54, P > 0.05. Evaluation of the level of HBV 
DNA showed that patients with intermediate values of 
HBV DNA level between 2 000 IU/ml and 20 000 
IU/ml compared to patients with low values of HBV 
DNA (< 2 000 IU/ml) have 10 times more probability 
for liver fibrosis, (Exp(B) = 10.38) 95% CI for EXP (B): 
0.69-156.17, P > 0.05. Patients with qHBsAg level 
more than 1 000 IU/ml compared to patients with 
qHBsAg level of lower or equal than 1000 IU/ml have 
0.15 (Exp(B) = 0.15) times lesser probability for liver 
fibrosis insignificant in 95% CI for EXP(B): 0.01-1.87, 
P > 0.05. Patients with high HBV DNA level (>20 000 
IU/ml) compared to patients with low HBV DNA level 
(<2 000 IU/ml) have 3.50 times more probability for 
liver fibrosis, insignificant for 95% CI for EXP (B): 
0.14-88.72, P > 0.05 (Table 4). 
Table 4: Assessment of the logistic regression model 
  
B S.E. Wald df Sig. Exp(B) 
95% CI for 
EXP(B) 
  Lower Upper 
Step 1
a
 APRI -0.46 2.30 0.04 1 0.84 0.63 0.01 57.75 
FIB-4 2.23 1.24 3.24 1 0.07 9.34 0.82 106.54 
qHBsAg -1.88 1.28 2.17 1 0.14 0.15 0.01 1.87 
HBV DNA ≥2 000 IU/ml 
≤ 20 000 IU/ml 
2.34 1.38 2.86 1 0.09 10.38 0.69 156.17 
HBV DNA >20 000 IU/ml 1.25 1.65 0.58 1 0.45 3.50 0.14 88.72 
Constant -3.85 1.23 9.85 1 0.002 0.02   
а. Variable(s) entered on step 1: APRI. FIB-4. qHBs. HBV DNA ≥2 000 IU/ml ≤ 20 000 
IU/ml. HBV DNA >20 000 IU/ml; Abbreviations: APRI : Aspartate transaminase-to-platelet 
ratio index. FIB-4: Fibrosis index based on the four factors. qHBsAg: quantitative hepatitis 
B antigen. HBV DNA: hepatitis B virus deoxyribonucleic acid. 
 
Analysis of APRI index showed that the 
increase of APRI score for one single cut-off value 
decreases the probability for liver fibrosis for 0.63 
(Exp (B) = 0.63)/(37%) insignificant for 95% CI for 
EXP (B): 0.01-57.75, P > 0.05 (Table 4).  
 
Figure 1: Area in the ROC curve model for fibrosis is 0.840 (95% CI 
0.697-0.984), predicting the greater probability for fibrosis in 84% of 
all possible pairs of patients in which one has fibrosis, and the other 
does not 
 
In the analysis of the area of the receiver 
operating curves (ROC) evaluating all four 
noninvasive biomarkers, the value of 0.840 means 
that in 84% of all possible pairs of patients where one 
has fibrosis, and the other pair is without fibrosis, this 
model will have higher predictive probability for 
fibrosis (Figure 1). 
 
 
 
Discussion 
 
The data from our study indicate that the 
greatest probability for distinguishing fibrosis in 
patients with HBeAg-negative CHB has a FIB-4 index. 
The clinical significance and applicability of this index 
is based on the following observations: the 
progression of the liver disease is age-related, and the 
disease duration is proportional with severe fibrosis; 
advanced fibrosis leads to mitochondrial injury of the 
liver cells and greater elevation of AST; more 
advanced fibrosis is associated with 
thrombocytopenia due to secondary hypersplenism 
and decreased production of thrombopoietin by liver 
cells [12].  
Our study revealed that FIB-4 has the 
greatest significance in predicting liver fibrosis and 
that the increase of FIB-4 index for one single cut-off 
value increases the probability for fibrosis for 9 folds. 
The studies performed by Kim [10], as well as the 
study of Ma [14] showed that FIB-4 can be suitable for 
distinguishing significant and extensive fibrosis in 
patients with chronic hepatitis B. The Kim’s study 
showed that AUROC’s area of FIB-4 for predicting 
significant fibrosis, severe fibrosis and cirrhosis were 
0.865, 0.910 and 0.923, respectively. The study 
conducted by Ma [14] also found that FIB-4 and 
Lock’s model was the most effective models for 
distinguishing significant fibrosis in patients with 
chronic hepatitis B. A meta-analysis performed by Yin 
showed that FIB-4 has relatively high diagnostic value 
for detecting liver fibrosis in patients with hepatitis B 
when the diagnostic threshold value was more than 
2.0. Similar to these studies, our report shows that 
patients, who had significant fibrosis, have about 9.3 
fold greater chance of being FIB-4 positive (above 
1.45) compared to patients without significant fibrosis. 
Analysis of the impact of serum level of HBV 
DNA showed that intermediate high serum level of 
HBV DNA compared to high HBV DNA viraemia has 
higher significance in predicting liver fibrosis. Patients 
with HBV DNA levels ranging between 2 000 IU/ml 
and 20 000 IU/ml have 10 times more probability for 
liver fibrosis compared to patients with HBV DNA 
levels less than 2000 IU/ml, while patients with HBV 
DNA levels above 20 000 IU/ml have 3.50 times more 
probability for liver fibrosis compared to patients with 
HBV DNA level lower than 2000 IU/ml. Comparatively, 
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the study by Croagh [27] found that HBV DNA level 
was a predictor of significant fibrosis in HBeAg-
negative CHB patients with varying ALT with an OR of 
1.3 for every 1 log increment. HBV DNA levels also 
correlated with advanced fibrosis in HBeAg-negative 
CHB patients with normal ALT and varying ages as 
reported in the study of Xiao et al., [28]. In contrast, 
Shao reported that HBV DNA levels had no significant 
statistical association with liver histology regardless of 
HBeAg status [29]. It is known that HBV itself is not 
directly cytopathic and host immune response plays a 
pivotal role in HBV-related liver diseases [2] [30]. The 
role of HBV DNA in correlation with liver histology in 
HBeAg negative patients remains controversial 
because different methods and assays have been 
used in different studies [31]. Zacharakis et al., [32] 
reported that it is beneficial to follow HBV DNA levels 
in CHB patients who are HBeAg negative, as the HBV 
DNA levels correlate with the progression of hepatic 
damage. According to the data obtained from the 
patients included in our study, the level of HBV DNA is 
associated with the progression of fibrosis. In our 
study, patients with low HBV DNA viraemia have 3.5 
and 10 times lower chance for liver fibrosis compared 
to the patients with intermediate and high HBV DNA 
level, respectively.  
Quantitative Hepatitis B surface antigen 
represents a marker of CHB related liver damage, and 
qHBsAg levels are linked with progression of liver 
disease in HBeAg-negative patients [33]. Our study 
shows that patients with a qHBsAg level higher than     
1 000 IU/ml compared to patients with a qHBsAg level 
lower or equal to 1000 IU/ml have 0.15 times lower 
probability for liver fibrosis. Patients who have lower 
qHBsAg level are associated with a higher probability 
of liver fibrosis. Our finding is discordant with the 
findings from several studies which reported that 
lower HBsAg levels are found in “inactive carrier” 
patients rather than in HBeAg-negative patients with 
“active” chronic hepatitis B [34] [35]. It is found that 
HBsAg production is reflective not only of cccDNA 
transcriptional activity
 
but also originates from the 
integrated DNA in hepatocytes [16] [17] [34]. 
In contrast, it has been shown that the 
presence of mutations within the pre-S/S region 
reduces HBsAg production [36]. Patients with more 
advanced liver disease and liver cirrhosis had more 
frequent changes in the pre-S/S regions. This could, 
therefore, explain the lower total levels of qHBsAg in 
patients with advanced liver disease [34].
 
The study of 
Martinot-Peignoux [37]
 
showed that there is a strong 
correlation between the stage of fibrosis and HBsAg 
level, but in HBeAg positive patients, while in patients 
with HBeAg negative CHB, qHBsAg was not found to 
be associated with any significant liver histologic 
changes. Unlike Martinot study, our study did not 
include patients with HBeAg positive CHB. Results 
from our study show that patients with high level of 
quantitative HBsAg (> 1000 IU/ml) have insignificant, 
but still, the lesser probability for liver fibrosis. This 
can be a result of the pre-S/S region mutation found in 
patients with CHB genotype D or as a result of 
decreased liver cell mass associated with more 
extensive fibrosis. Unfortunately, in our institution, 
there is no possibility to perform HBV genotyping and 
detecting mutations. 
In patients included in our cohort, the 
observed APRI score showed that it has the lowest 
prediction for liver fibrosis. The increase of APRI 
score for one single cut-off value decreases the 
probability for liver fibrosis for 0, 63 folds. Our finding 
is consistent with findings from the other studies which 
showed that APRI test designed as the “perfect 
noninvasive model” to evaluate liver fibrosis, has only 
moderate sensitivity and accuracy for assessing HBV 
related fibrosis [38].  
At present, accurate diagnosis of liver fibrosis 
is essential for the prevention of disease progression 
and treatment of chronic liver disease. In our study, 
we evaluated the association of noninvasive 
biomarkers FIB-4, APRI, quantitative hepatitis B 
antigen and serum level of HBV DNA in correlation 
with transient elastography. The appraised clinical 
parameters age, platelet count, aspartate 
transaminase alanine transaminase, ultrasound and 
fibroscan in detecting liver fibrosis, correlate with 
noninvasive biomarkers in predicting liver fibrosis. 
Overall, our study shows that FIB-4 has the greatest 
predictive value for liver fibrosis in our patients with 
hepatitis be negative antigen CHB. 
In conclusion, a whole plead of noninvasive 
markers is available for the determination of fibrosis 
and monitoring the progression and regression of 
fibrosis in chronic HBV patients. It appears that a 
combination of blood and imaging tests can provide 
the highest diagnostic accuracy and exclude the need 
for liver biopsy. Our study shows that FIB-4 index has 
the greatest impact in predicting liver fibrosis and that 
more advanced liver disease is associated with lower 
serum level of quantitative HBs antigen. It will be a 
challenge to define the best clinical strategy on how to 
apply validated noninvasive tests in the management 
of patients with chronic HBV infection. The drawback 
of our study was that the sample size may have been 
too small, our incapacity for HBV genotyping and 
determining pre-S/S region mutations. Further studies 
involving a greater number of patients and 
combination of more noninvasive biomarkers are 
needed for better evaluation of the applicability of 
these markers in distinguishing liver fibrosis.  
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